Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 801–900 of 1,733
Hypogonadism in men: Updates and treatments
Ugo-Neff, G., & Rizzolo, D. (2022) · JAAPA · doi:10.1097/01.jaa.0000824956.78048.ff · Cited by 9
Breaking Down Bone Disease in People Living with HIV: Pathophysiology, Diagnosis, and Treatment
Hasenmajer, V., D'Addario, N. F., Bonaventura, I., Sada, V., Nardi, C., Jannini, E. A., d’Ettorre, G., Mastroianni, C. M., & Gianfrilli, D. (2024) · Advances in experimental medicine and biology · doi:10.1007/5584_2024_831 · Cited by 9
PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study
Meunier, M. E., Neuzillet, Y., Dreyfus, J., Schneider, M., Rouprêt, M., Cathelineau, X., Raynaud, J., Lebrét, T., & Botto, H. (2021) · World Journal of Urology · doi:10.1007/s00345-020-03557-6 · Cited by 9
Contribution of Androgen Receptor CAG Repeat Polymorphism to Human Reproduction
Ciarloni, A., Muti, N. D., Ambo, N., Perrone, M., Rossi, S., Sacco, S., Salvio, G., & Balercia, G. (2025) · DNA · doi:10.3390/dna5010009 · Cited by 6
“…leads to the consequence that active breast cancer represents an absolute contraindication to testosterone replacement therapy in hypogonadal men [65], but at the same time, makes the AR gene a possible target for future hormone therapy in AR -positive breast cancers that are unresponsive to…”
Cardiovascular Health of Youth During Gender-Affirming Testosterone Treatment: A Review
Kean, A. C., Saroufim, R., Meininger, E. T., Fuqua, J. S., & Fortenberry, J. D. (2021) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2021.08.009 · Cited by 10
Spaggiari, G., Costantino, F., Valentina, L. D., Romeo, M., Furini, C., Roli, L., Santis, M. C. D., Canu, G., Trenti, T., Granata, A. R. M., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03717-3 · Cited by 8
“This threshold was considered evaluating the de fi nition of normal testosterone serum levels in most of guidelines published on the topic [34, 41 – 43].”
BackgroundInfluentialThe, S. T., Hung, N. B., Hiền, L. T. T., Tuan, N. A., Pho, D. C., Dung, Q. A., Anh, D. D., Quang, H. D., Van, A. H., & Hung, P. N. (2021) · Research and Reports in Urology · doi:10.2147/rru.s315056 · Cited by 6
“Our therapy increased serum testosterone level, which in turn induced and maintained secondary sex characteristics and also improved the quality of life and well-being, especially in patients aiming to become fertile.(23) Testosterone level increased by approximately 25 times (mean) and was at a normal range at 12 mon…”
BackgroundThe Effects of Testosterone Treatment on Cardiovascular Health
Jayasena, C. N., Ho, C. L. T., & Bhasin, S. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.006 · Cited by 6
Self-citationHypogonadismus und Infertilität des Mannes
Zitzmann, M. (2019) · Gynäkologische Endokrinologie · doi:10.1007/s10304-019-00277-y · Cited by 4
Anupam, B., Shivaprasad, C., Atluri, S., Aiswarya, Y., Gautham, K., Barure, R., & Shah, K. (2019) · International Journal of Impotence Research · doi:10.1038/s41443-019-0144-9 · Cited by 7
“Hence, the guidelines recommend that an equation based on TT, SHBG, and serum albumin levels that accurately reflects the free testosterone level can be used when equilibrium dialysis estimation is not possible [6].”
BackgroundHashimi, M. A., Pinggera, G., Shah, R. S., & Agarwal, A. K. (2025) · Asian Journal of Andrology · doi:10.4103/aja2024104 · Cited by 12
“11,57,58 Usually, serum testosterone levels are higher than normal during the course of ET and significantly lower than normal soon after the discontinuation of ET.”
Medical Treatment of Hypogonadism in Men
Mani, S. B., & Clavijo, R. I. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2021.12.008 · Cited by 7
Exploring obesity-related endocrine disorders beyond diabetes: a narrative review
Meligi, A. A. H. E., Ahmed, R. M., Shaltout, I., & Soliman, A. R. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00358-w · Cited by 9
“Hence, severe obesity is regarded as one of the causes of functional secondary hypog-onadism [50, 51].”
BackgroundInfluentialTesticular Involvement is a Hallmark of Apo A-I Leu75Pro Mutation Amyloidosis
Delbarba, A., Facondo, P., Fisogni, S., Izzi, C., Maffezzoni, F., Pezzaioli, L. C., Lodovico, E. D., Facchetti, F., Cappelli, C., Scolari, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa587 · Cited by 6
Castets, S., Albarel, F., Bachelot, A., Brun, G., Bouligand, J., Briet, C., Quoc, E. B., Cazabat, L., Chabbert‐Buffet, N., Christin‐Maître, S., et al. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.03.001 · Cited by 6
Gómez-Lumbreras, A., & Zapata, L. V. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241231612 · Cited by 5
“23 According with FAERS gender reassignment reports, there were a total of 12 ADRs of breast cancer among transgender men using testosterone.”
Dietary patterns and testosterone balance: a review of clinical data and perspectives
Liu, X., Li, X., Cai, D., Sun, J., & Bai, W. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.016 · Cited by 6
“In addition to their energetic role, ketone bodies function as anorexigenic agents, directly suppressing appetite ) [207].”
Bowel preparation for colonoscopy may decrease the levels of testosterone in Korean men
Lee, S.-H., Park, S. G., Kim, M. J., Chun, H., Cho, D., Hong, D., & Kim, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-43598-5 · Cited by 6
Tsampoukas, G., Karna, S., Morgado, A., & Minhas, S. (2025) · International Journal of Impotence Research · doi:10.1038/s41443-025-01128-0 · Cited by 8
“Finally, the EnS panel de fi ned MH as a clinical syndrome that results from failure of the testis to produce physiological concentrations of T and/or a normal number of spermatozoa due to pathology at one or more levels of the HPT axis [28].”
InfluentialSelvam, M. K. P., Baskaran, S., Tannenbaum, J., Greenberg, J. W., Shalaby, H., Hellstrom, W. J. G., & Sikka, S. C. (2023) · Medicina · doi:10.3390/medicina59111902 · Cited by 8
“Testosterone replacement therapy (TRT) is the mainstay treatment for symptomatic male hypogonadism and is designed to restore testosterone levels in individuals with low testosterone [10].”
BackgroundPituitary Dysfunction Among Men Presenting with Hypogonadism
Levy, S., Arguello, M., Macki, M., & Rao, S. D. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0935-z · Cited by 6
Effects of testosterone and exercise training on bone microstructure of rats
Baptista, C. J., Faustino‐Rocha, A. I., Fardilha, M., Ferreira, R. M., Oliveira, P. A., Regueiro-Purriños, M. M., Rodríguez-Altónaga, J. A., Gonzalo-Orden, J. M., & Ginja, M. (2022) · Veterinary World · doi:10.14202/vetworld.2022.627-633 · Cited by 10
Firouzi, V., Boroujeni, P. B., Talab, Z. R., Mohammadi, M., Gilani, M. A. S., Sabbaghian, M., & Meybodi, A. M. (2019) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2019.1590478 · Cited by 4
“terone deficiency can induce and maintain secondary sex characteristics and correct symptoms of hypogonadism (Bhasin et al. 2018).”
BackgroundLow free testosterone is associated with increased mortality in frail surgical patients
Lin, F., Hong, G., Kwon, F. Y., Pirani, F., Makhani, S. S., Henry, M. A., Cooke, I. J., Nabavizadeh, R., Midenberg, E. R., Mehta, A., et al. (2021) · Surgery Open Science · doi:10.1016/j.sopen.2021.11.002 · Cited by 6
“Total and free T levels were assessed as normal or low based on the reference ranges provided by the Endocrine Society and Quest Diagnostics (Appendix A).”
MethodResultInfluentialSlettvoll, T., Wahlberg, J., Lood, Y., Josefsson, M., Aardal, E., & Salihović, S. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-06005-9 · Cited by 11
“The method sensitivity and multiplexing capacity make it valuable in clinical scenarios such as the evaluation of hypo-gonadism (45) or follow-up testing in prostate cancer patients receiving anti-androgens (46) (Addison’s disease, congenital adrenal hyperplasia), where hormone concentrations may…”
Hypogonadism management and cardiovascular health
Auerbach, J. M., & Khera, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1805917 · Cited by 6
Muscle Strength and Male Sexual Function
Viken, A. F., Siiak, S. P., Schlünssen, V., Thorarinsdottir, E. H., Skulstad, S. M., Gyawali, S., Bertelsen, R. J., & Real, F. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020426 · Cited by 9
“Trying to account for this, we did analyses controlling for beard growth and hot flushes, symptoms that can associate with low T [49,50].”
BackgroundLiu, Y., Huang, C., Du, J., Lan, G., Du, X., Sun, Y., & Shi, G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.915159 · Cited by 5
Kim, G. Y., Conduit, C., O’Haire, S., Chong, C. Y., Baenziger, O., Lewin, J. H., Thomas, B., Lawrentschuk, N., Stockler, M. R., Olver, I., et al. (2024) · Basic and Clinical Andrology · doi:10.1186/s12610-024-00230-5 · Cited by 6
“Guidelines recommend addressing reversible causes prior to initiating TRT in certain conditions that cause hypogonadism, such as obesity [28].”
BackgroundBarnett, N., Ljubic, M., Chung, J. S., & Capizzi, A. N. (2024) · Neurorehabilitation · doi:10.3233/nre-230291 · Cited by 4
“%) of the 6 testosterone users in this study met current Endocrine Society guidelines for establishing a diagnosis of hypogonadism prior to initiation of testosterone (Bhasin et al., 2018).”
InfluentialIshay, A., Tzemah, S., Nitzan, R., Jehassi, A., & Cohen, M. (2019) · Sexual Medicine · doi:10.1016/j.esxm.2019.06.011 · Cited by 5
“Nearly half of the endocrinologists and more than half of the urologists were unaware that acute illnesses may cause a transient decrease in testosterone concentrations and that it is not recommended to perform testing for testosterone deficiency around and during acute disease.(1,10,19)”
BackgroundMethodInfluentialTreatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members
Butaney, M., Thirumavalavan, N., Balasubramanian, A., McBride, J. A., Gondokusumo, J. C., Pastuszak, A. W., & Lipshultz, L. I. (2020) · Urology · doi:10.1016/j.urology.2020.01.032 · Cited by 6
“its management from other major societiessuch as the European Association of Urology (EAU) and the Endocrine Society are also lacking.(12, 18) We hypothesize that the lack of data and guidelines are likely leading to highly variable practice patterns.”
BackgroundManov, A. (2020) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000153 · Cited by 4
Tiecco, G., Delbarba, A., Colangelo, C., Gregorio, M. D., Facondo, P., Riva, M., Cappelli, C., Focà, E., Castelli, F., & Quirós-Roldán, E. (2025) · Andrology · doi:10.1111/andr.70050 · Cited by 7
Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis
Ferrari, V., Terlizzi, V., & Stagi, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144041 · Cited by 7
Caretta, N., Scafa, R., Graziani, A., Crepaldi, M. C., Vedovato, M., Avogaro, A., & Ferlin, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad586 · Cited by 7
Male Reproductive Endocrinology
Tsametis, C. P., Kanakis, G., & Goulis, D. G. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009197533.006 · Cited by 8
Cardiovascular disease and testosterone therapy in male hypogonadism
de Silva, N. L., Grant, B., Minhas, S., & Jayasena, C. N. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15211 · Cited by 13
“9,10 A subsequent individual participant data (IPD) meta-analysis 11 and a dedicated cardiovascular outcome trial 12 have improved our understanding of the cardiovascular effects of testosterone in men with hypogonadism.”
Bøgehave, M., Glintborg, D., Gram, J., Bladbjerg, E., Andersen, M., & Sidelmann, J. J. (2023) · Endocrine Connections · doi:10.1530/ec-22-0455 · Cited by 9
Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 7
“However, the risks of serious adverse effects increase in patients with a high risk of prostate cancer, already-present prostate or breast cancer, palpable prostate nodules, already-high PSA and certain hearth issues—for these patients, TRT is not recommended [134].”
Zhang, Q., Chen, W., Yun, C., & Wang, J. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00765-y · Cited by 5
Recent advancements and various potential applications of transdermal patches
Razzaq, A. A., Riaz, T., Zaman, M., Waqar, M. A., & Ashfaq, A. (2024) · International Journal of Polymeric Materials · doi:10.1080/00914037.2023.2299784 · Cited by 8
“Contrarily, testosterone is a medication that has been utilized to treat male hypogonadism [80] .”
Early Life Androgen Administration Attenuates Aging Related Declines in Muscle Protein Synthesis
Church, D. D., Zamir, A., Escalante, G., Ben‐Zeev, T., Levi, C., Ferrando, A. A., & Hoffman, J. R. (2024) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003402 · Cited by 5
“Clinically, these substances may be utilized to treat various medical conditions, and patients are often under clinical guidance to minimize the likelihood of potential adverse events (1,4).”
BackgroundHypogonadism and urologic surgeries: a narrative review
Fendereski, K., Ghaed, M. A., Calvert, J. K., & Hotaling, J. M. (2022) · Translational Andrology and Urology · doi:10.21037/tau-22-308 · Cited by 5
“Free testosterone is mainly calculated upon accurate measurement of total testosterone, SHBG, and albumin using different available formulas based on the binding characteristics of testosterone to SHBG and albumin (3,13).”
BackgroundMethodInfluentialSexual Dysfunction in Chronic Kidney Disease
Johansen, K. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00037-1 · Cited by 6
Raharinavalona, S. A., Chevalier, N., Gruel, C., Ntoutoum, A., & Vélayoudom, F.-L. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13089 · Cited by 4
Testosterone therapy in children and adolescents: to whom, how, when?
Arbeláez, M. C. S., Israeli, J. M., Kresch, E., Telis, L., & Nassau, D. E. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00525-5 · Cited by 8
“Although guidelines for following adults on TT are highly standardized [119], there is scant guidance for adolescents and children [25, 98], and systematic monitoring is not routinely practiced [121, 129].”
BackgroundWu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101626 · Cited by 6
Self-citationLiang, G.-Q., Song, Y., Wang, X. D., Li, J., Shi, H., Zhu, Q., Zheng, J.-B., Yu, X., Zheng, L., Zhang, S., et al. (2021) · Sexual Health · doi:10.1071/sh20201 · Cited by 6
Martinez-Arguelles, D. B., Nedow, J., Gukasyan, H. J., & Papadopoulos, V. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003017 · Cited by 7
New Horizons: Testosterone or Exercise for Cardiometabolic Health in Older Men
GREEN, D. J., Chasland, L. C., Naylor, L. H., & Yeap, B. B. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad175 · Cited by 5
Otzel, D. M., Nichols, L., Conover, C. F., MARANGI, S. A., Kura, J. R., Iannaccone, D. K., Clark, D. J., Gregory, C. M., Sonntag, C. F., Wokhlu, A., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1479264 · Cited by 7
Eat clen? The normalisation of harmful clenbuterol use within digital fitness cultures
Cox, L. T. J., & Piatkowski, T. M. (2025) · Performance Enhancement & Health · doi:10.1016/j.peh.2025.100391 · Cited by 6
Huynh, L. M., Huang, E., Towe, M. M., Liang, K., el Khatib, F. M., Yafi, F. A., & Ahlering, T. E. (2021) · British Journal of Urology · doi:10.1111/bju.15626 · Cited by 6
Zhang, J., Shen, Y., Li, G., Zhang, F., Yang, A., Li, J., Pu, S., Huang, Q., Zhuang, B., & Yu, X. (2023) · International Journal of Impotence Research · doi:10.1038/s41443-023-00803-4 · Cited by 7
“Male hypogonadism is a condition characterized by insuf fi cient production of testosterone and/or reduced numbers of spermatozoa, which may result from lesions found anywhere along the hypothalamic-pituitary-testicular axis (HPT) [1].”
Antonič, K. G. (2022) · The Aging Male · doi:10.1080/13685538.2022.2134338 · Cited by 8
Feng, X. G., Xia, K., Ke, Q., Deng, R., Zhuang, J., Wan, Z., Luo, P., Wang, F., Zang, Z., Sun, X., et al. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111039 · Cited by 7
Chang, S., Pedersen, L. H., Skakkebaek, A. H., Berglund, A., & Gravholt, C. H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf619 · Cited by 7
Rizzuti, A., Alvarenga, C., Stocker, G., Fraga, L., & Santos, H. O. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.003 · Cited by 10
Antonič, K. G., & Zitzmann, M. (2023) · The Aging Male · doi:10.1080/13685538.2023.2296460 · Cited by 8
The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems
Antonič, K. G., & Zitzmann, M. (2025) · The Aging Male · doi:10.1080/13685538.2025.2601423 · Cited by 7
“According to the guidelines [5,6] treatment of male hypogonadism include weight reduction and testosterone replacement, which is supported by many clinical studies.”
InfluentialDeficiência de Testosterona em Homens Hipertensos: Prevalência e Fatores Associados
Negretto, L. A. F., Rassi, N., Soares, L. R., Saraiva, A. B. C., Teixeira, M. E. F., Santos, L. D. R., Souza, A. L. L., Jardim, P. C. B. V., Barroso, W. K. S., & Jardim, T. V. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230138 · Cited by 12
Pandemic of testosterone abuse: Considerations for male fertility
Kumar, N., V, Kakoti, S., & Chung, E. (2025) · Arab Journal of Urology · doi:10.1080/20905998.2025.2509456 · Cited by 6
“The endocrine society guidelines recommend testosterone therapy in patients with clinical features of hypogonadism along with low testosterone levels checked multiple times [42].”
Pagadala, M. S., Jasuja, G. K., Palnati, M., Lynch, J. A., Anglin-Foote, T. R., Chang, N., Deka, R., Lee, K. M., Agiri, F. Y., Seibert, T. M., et al. (2022) · medRxiv · doi:10.1101/2022.02.16.21265846 · Cited by 7
Vignera, S. L., Condorelli, R. A., Calogero, A. E., Cannarella, R., Mongioì, L. M., Duca, Y., Cimino, L., Giacone, F., & Aversa, A. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.48 · Cited by 6
“, 200 to 400 ng/dL) of normal range (7).”
BackgroundInfluentialVariability in SHBG assays and the effect thereof on calculated estimates of free testosterone
Walravens, J., Adaway, J., Reyns, T., Narinx, N., Nyamaah, J. A., Antonio, L., Jean-Marc, K., Keevil, B. G., Fiers, T., & Lapauw, B. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251350676 · Cited by 6
Abuse of anabolic steroids: A dangerous indulgence
Gagliano‐Jucá, T., & Basaria, S. S. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.10.002 · Cited by 7
Testosterone Therapy and Prostate Cancer
Morales, Á., & Siemens, D. R. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.07.002 · Cited by 4
Diabetes and Hypogonadism in Males
Lakshmi, G., & Mahadevan, S. (2025) · Apollo Medicine · doi:10.1177/09760016251332088 · Cited by 5
“[1] An Indian consensus group suggested the use of testosterone replacement in men with T2DM and functional hypogonadism (serum total testosterone <2.3 ng/ml; <8 nmol/l) with sexual dysfunction after discussing the risks versus benefits.”
InfluentialJasuja, G. K., Engle, R. L., Skolnik, A. A., Rose, A. J., Male, A. M., Reisman, J. I., & Bokhour, B. G. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05270-6 · Cited by 4
Effect of Androgen Deficiency on the Condition of Carbohydrate Metabolism in Men
Mkrtumyan, A. M., Yegshatyan, L. V., & Shishkova, Y. A. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-12-56-66 · Cited by 4
“Таким образом, целью заместительной терапии тестостероном является улучшение клинических симптомов и достижение уровня тестостерона, соответствующего средненормальным значениям у здоровых молодых мужчин (14,0–17,5 нмоль/л) [49].”
A Critique of the AUA Guidelines on Testosterone Deficiency
Morgentaler, A., Traish, A. M., & Khera, M. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.10.019 · Cited by 4
Testosterone Replacement, Where Are We in 2025?
Walia, A., Coady, P. J., Sofia‐Hernandez, B., Gudlavalleti, H., El-Achkar, A., Dunnam, S. E., Madhusoodanan, V., Kohn, T. P., & Khera, M. (2025) · Trends in Urology & Men s Health · doi:10.1002/tre.70016 · Cited by 6
“Current best practice requires two separate morning testosterone measurements (8:00 – 10:00 AM, fasting) to account for circadian variation and reduce diagnostic errors by approximately 30% [14].”
InfluentialHypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy
Canu, L., Sparano, C., Naletto, L., Filpo, G. D., Cantini, G., Rapizzi, E., Martinelli, S., Ercolino, T., Cioppi, F., Fantoni, A., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1320722 · Cited by 5
Laru, J., Pinola, P., Ojaniemi, M., Korhonen, E., Laikari, L., Franks, S., Piltonen, T., Tapanainen, J. S., Niinimäki, M. J., & Morin-Papunen, L. C. (2023) · Andrology · doi:10.1111/andr.13492 · Cited by 4
Smith, C., Contreras-Garza, J., Cunningham, R. L., Wong, J. M., Vann, P. H., Metzger, D. B., Kasanga, E. A., Oppong‐Gyebi, A., Sumien, N., & Schreihofer, D. A. (2019) · Neuroendocrinology · doi:10.1159/000504445 · Cited by 4
Expert Opinion on the Diagnosis and Management of Male Hypogonadism in India
Kalra, S., Jacob, J. J., Unnikrishnan, A., Bantwal, G., Sahoo, A., Sahay, R. K., Jindal, S., Agrawal, M. S., Kapoor, N., Saboo, B., et al. (2023) · International Journal of Endocrinology · doi:10.1155/2023/4408697 · Cited by 4
“Among Indian men above 40 years of age, the prevalence is 20%–48% [4, 5].”
BackgroundInfluentialSheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery
Stumpf, M. A. M., Cercato, C., de Melo, M. E., & Mancini, M. C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09946-9 · Cited by 5
“Other comorbidities such as type 2 diabetes [37] and hypogonadism [38] might also play a role in determining muscle loss after the procedure.”
Testosterone deficiency in male organ transplant recipients
Omil-Lima, D., Jesse, E., Gupta, K., Sellke, N. C., Muncey, W. W., Burrelli, C. C., Ghayda, R. A., Loeb, A., & Thirumavalavan, N. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00513-9 · Cited by 4
“Although some professional societies have published consensus guidelines against TTh in men with advanced heart disease, current AUA guidelines maintain that data is insufficient to determine whether TTh increases or decreases the risk of cardiovascular events, given that cardiac outcomes in hypogonadal men are also p…”
BackgroundTestosterone therapy: where do the latest guidelines agree and differ?
Pelzman, D. L., & Hwang, K. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000581 · Cited by 6
Congenital Hypogonadotropic Hypogonadism with Early-Onset Coronary Artery Disease
Takashima, A., Yagi, S., Yamaguchi, K., Kurahashi, K., Kojima, Y., Zheng, R., Ise, T., Kusunose, K., Yoshida, S., Yamada, H., et al. (2021) · The Journal of Medical Investigation · doi:10.2152/jmi.68.189 · Cited by 4
Cai, L., Xie, H., Li, W., Chen, C., Li, T., Xu, L., Mao, Y., Liang, J., Wen, J., & Chen, G. (2025) · Endocrine · doi:10.1007/s12020-025-04199-7 · Cited by 5
Testosterone Therapy in Adult Males with Hypogonadism
Boeri, L., Masterson, T., Antonio, L., Corona, G., Khera, M., Salonia, A., & Mulhall, J. P. (2025) · European Urology · doi:10.1016/j.eururo.2025.12.015 · Cited by 10
Coden, G. S., Travers, H. I., Kuznetsov, M., Kirsch, J. M., Bono, J. V., & Smith, E. L. (2025) · The Journal of Knee Surgery · doi:10.1055/a-2608-0156 · Cited by 5
“12,13 Further insight into the speci fi c levels in these patients would be useful.”
Correlation between pan immune inflammation value and testosterone deficiency risk increase
Tong, L., & Chen, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-98517-8 · Cited by 4
“According to the clinical practice guidelines of the Endocrine Society and the guidelines of the American Urological Association, TD 300 ng/dl is considered the threshold for low testosterone 16,17 .”
Fasting Versus Non-Fasting Total Testosterone Levels in Women During the Childbearing Period
Ali, E. B., Hamza, A., Zaboon, I. A., Alidrisi, H. A., & Mansour, A. A. (2023) · Cureus · doi:10.7759/cureus.35462 · Cited by 6
“Introduction The total testosterone levels in men should be measured in the fasting state in early in the morning with at least two samples according to guidelines [1,2].”
BackgroundApproach to the Patient: New Era Emerges for Craniopharyngioma Management
Hayes, A. G., Jonker, B., Teng, C., Lemech, C., Killen, A. J., Sim, H., & McCormack, A. I. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae503 · Cited by 4
Holley-Mallo, R., & Golden, A. K. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.004 · Cited by 5
Overt hypogonadism is a cardiovascular risk factor in type 2 diabetic males: An observational study
Oğuz, A., Şahin, M., Ülgen, C., Uyan, M., & Gül, K. (2021) · Andrologia · doi:10.1111/and.14271 · Cited by 5
Rathi, N., Blake, Z., Hyman, J., Nemirovsky, D., Gelikman, D. G., Hesswani, C., Koller, C. R., Nethala, D., Mendhiratta, N., Kenigsberg, A. P., et al. (2024) · Urology · doi:10.1016/j.urology.2024.10.006 · Cited by 4
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
“The effects of testosterone replacement therapy on lipids appear partly mediated by improvements in body composition and partly by direct actions on hepatic lipase and lipoprotein lipase, though results remain heterogeneous and highlight the importance of individualized monitoring [321, 322].”
Bedimo, R., Hardy, D., Lee, D., Palella, F. J., & Wohl, D. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae407 · Cited by 4
“Patients with hypo-gonadism should be screened and treated with recommended therapies such as testosterone [78].”
BackgroundZacharia, S. S., Thomas, R., Johnson, J. T., Kapoor, N., Ramanathan, S., Asha, H. S., Cherian, K. E., & Paul, T. V. (2024) · Pituitary · doi:10.1007/s11102-024-01433-9 · Cited by 5
“Hypogonadism is characterized by low morning serum total and/or free tes - tosterone levels combined with symptoms and signs of testosterone deficiency [ 16 ].”
Morbidity and mortality in men: Role of androgens
Fallara, G., Pozzi, E., Corsini, C., Belladelli, F., Boeri, L., Capogrosso, P., Montorsi, F., & Salonia, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101662 · Cited by 5
Sexual Dysfunction in Chronic Kidney Disease
Santoro, D., Gembillo, G., Satta, E., & Bellinghieri, G. (2023) · Springer eBooks · doi:10.1007/978-3-031-42045-0_26 · Cited by 5
Pastuszak, A. W., Bush, M., Curd, L., et al. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1939 · Cited by 4
Vogiatzi, M. G., Jaffe, J. S., Amy, T., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad059 · Cited by 4
“Many new testosterone formulations have been developed to overcome difficulties with administration and adverse events, but these are supported only by expert opinion and are not evidence based [3, 4].”
BackgroundHormonersatztherapie des Mannes
Zitzmann, M. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-118752 · Cited by 4
“Angeborene numerische Chromosomenaberrationen wie das unterdiagnostizierte Klinefelter-Syndrom (Karyotyp 47,XXY, siehe unten) sind im klinischen Verlauf oft mit der Entwicklung eines hypergonadotropen Hypogonadismus vergesellschaftet [1, 3].”
InfluentialTestosterone, HIV, and cardiovascular disease risk
Grant, J. K., Loyd, Q., & Martinez, C. A. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000236 · Cited by 4
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.